Used in targeted cancer therapy, particularly for solid tumors expressing CEACAM6 such as pancreatic, colorectal, and lung cancers. Binds specifically to CEACAM6 on tumor cells, enabling immune-mediated destruction through mechanisms like antibody-dependent cellular cytotoxicity (ADCC). Investigated in clinical trials to block tumor growth and metastasis by interfering with CEACAM6-mediated cell adhesion and signaling. Also explored as a delivery vehicle for conjugated drugs or radionuclides to enhance tumor specificity. Shows potential in imaging applications for detecting CEACAM6-positive lesions.